Trial Profile

A Non Randomized, Open Label, Phase II Trial to Assess the Efficacy and Safety of Bevacizumab Plus Capecitabine and Oxaliplatin, as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polichemotherapy Treatment.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Aug 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms BECOX

19 Jun 2014 Status changed from active, no longer recruiting to completed according to results published in the British Journal of Cancer.
29 Jan 2014 Planned End Date changed from 1 Dec 2012 to 1 Mar 2014 as per ClinicalTrials.gov record.
20 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com